An artificial intelligence (AI)-based risk prediction model, ONCO-ACS, showed possible favorable clinical utility as a practical tool for predicting cardiovascular death, myocardial infarction, and ischemic stroke events in patients with cancer and acute coronary syndrome, according to findings from a model development and validation study published in The Lancet.
Using these data, treatments for these patients could be individualized to better account for their risks of subsequent cardiac events.
“To provide targeted treatment for these patients, clinicians need more accurate tools to assess individual risk profiles,” stated first study author Florian A. Wenzl, MD, from the Center for Molecular Cardiology at the University of Zurich and the National Health Service England.
Study Methods
Researchers sought to create a risk score for events of mortality, bleeding, and ischemic events in patients with cancer and acute coronary syndrome.
The researchers tested models with machine learning techniques to predict all-cause mortality, major bleeding events, and ischemic events for patients with cancer and acute coronary syndrome. Between the development and validation sets, the risk prediction models were tested on data from 1,017,759 patients with cancer who had a heart attack in England, Sweden, and Switzerland. The final model was the ONCO-ACS score, which was also externally validated on a distinct dataset.
Key Findings
Patients with cancer and acute coronary syndrome had a cumulative incidence of mortality of 27.8% (95% confidence interval [CI] = 27.3%–28.3%), 7.3% for major bleeding events (95% CI = 7.0%–7.5%), and 16.1% for ischemic events (95% CI = 15.7%–16.4%). These patients also had a distinct risk profile compared with patients with cancer without acute coronary syndrome.
The factors that influenced the ONCO-ACS risk score included tumor type, time since cancer diagnosis, metastatic disease or not, age, hemoglobin levels, heart rate, estimated glomerular filtration rate, body mass index, Killip class, cardiac arrest, and major bleeding within 6 months.
The time-dependent area under the receiver operating characteristic curve for the risk prediction model was 0.84 (95% CI = 0.83–0.85) for all-cause mortality, 0.70 (95% CI = 0.68–0.73) for major bleeding events, and 0.79 (95% CI = 0.78–0.81) for ischemic events at 6 months. When externally validated, the risk prediction tool achieved a time-dependent area under the receiver operating characteristic curve of 0.80 to 0.84 for all-cause mortality at 6 months, depending on the location of the patient, 0.67 to 0.74 for major bleeding events, and 0.70 to 0.76 for ischemic events.
When the model was applied to current guidelines, the risk prediction score suggested that most of the patients with cancer and acute coronary syndrome would qualify for invasive management and long-term dual antiplatelet therapy. “Depending on the tumor characteristics, cancer patients can be at elevated risk of bleeding, of arterial blood clotting, or both—each requiring different anti-platelet medication for secondary prevention after the acute event,” noted Dr. Wenzl.
“By accounting for both cancer and heart disease, ONCO-ACS marks a step towards truly personalized medicine. It can help doctors decide who benefits from invasive procedures and intensive drug therapy, and who may be at greater risk of harm,” said senior author Thomas F. Lüscher, MD, from the National Heart and Lung Institute, Imperial College London, and the Royal Brompton and Harefield Hospitals.
DISCLOSURE: For full disclosures of the study authors, visit thelancet.com.
